Evidence map›Paper›PMID 35107141›Full record

Trial reportThe Journal of antimicrobial chemotherapy2022

Simultaneous pharmacokinetic/pharmacodynamic (PKPD) assessment of ampicillin and gentamicin in the treatment of neonatal sepsis.

Silke Gastine, Christina Obiero, Zoe Kane, Phoebe Williams, John Readman, Sheila Murunga, Johnstone Thitiri, Sally Ellis, Erika Correia, Borna Nyaoke and 5 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial
In one paragraph

Trial report in The Journal of antimicrobial chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03453177 (Intravenous and Oral Fosfomycin in Hospitalised Neonates With Clinical Sepsis), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03453177 phase2completednot on this map

Intravenous and Oral Fosfomycin in Hospitalised Neonates With Clinical Sepsis: an Open-label Safety and Pharmacokinetics Study (neoFosfo)

TypeinterventionalSponsorDrugs for Neglected DiseasesRan2018 to 2019Enrolled120ConditionsNeonatal SEPSISArmsStandard of Care + Fosfomycin, PK, Analysis of Bacterial Isolates
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 5 countries.

Silke GastineInfection, Immunity and Inflammation, Great Ormond Street Institute of Child Health, University College London, London, UK.
Christina ObieroKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Zoe KaneInfection, Immunity and Inflammation, Great Ormond Street Institute of Child Health, University College London, London, UK.ORCID 0000-0002-5596-8532
Phoebe WilliamsKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
John ReadmanInfection, Immunity and Inflammation, Great Ormond Street Institute of Child Health, University College London, London, UK.
Sheila MurungaQuotient Sciences, Mere Way, Ruddington, Nottingham, UK.
Johnstone ThitiriQuotient Sciences, Mere Way, Ruddington, Nottingham, UK.
Sally EllisGlobal Antibiotic Research & Development Partnership (GARDP), Genève, Switzerland.
Erika CorreiaGlobal Antibiotic Research & Development Partnership (GARDP), Genève, Switzerland.
Borna NyaokeDrugs for Neglected Diseases Initiative (DNDi), Nairobi, Kenya.
Karin KipperInstitute of Chemistry, University of Tartu, Tartu, Estonia.
John van den AnkerDepartment of Paediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, University of Basel, Switzerland.
Mike SharlandPaediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St. George's, University of London, London, UK.
James A BerkleyQuotient Sciences, Mere Way, Ruddington, Nottingham, UK.
Joseph F StandingInfection, Immunity and Inflammation, Great Ormond Street Institute of Child Health, University College London, London, UK.ORCID 0000-0002-4561-7173
Great Ormond Street Hospital · GBGlobal Antibiotic Research & Development Partnership · CHKenya Medical Research Institute · KEQuotient Clinical (United Kingdom) · GBChildren's National · USKenya AIDS Vaccine Initiative · KESt George's, University of London · GBUniversity of Oxford · GBUniversity of Tartu · EE

Funding

Department of HealthMedical Research Council MR/M007367/1Medical Research Council MR/M008665/1Wellcome Trust
6 · The paper itself

Abstract

objectivesThis study aimed to simultaneously investigate the pharmacokinetics of ampicillin and gentamicin, currently the WHO standard of care for treating neonatal sepsis.

methodsPharmacokinetic data were collected in 59 neonates receiving ampicillin and gentamicin for suspected or proven sepsis in the NeoFosfo trial (NCT03453177). A panel of 23 clinical Escherichia coli isolates from neonates with sepsis, resistant to either ampicillin, gentamicin or both, were tested for susceptibility using chequerboards. Pharmacokinetic/pharmacodynamic (PKPD) modelling and simulations were used to compare single-agent (EUCAST MIC) and combination (chequerboard MIC) target attainment with standard dosing regimens.

resultsA model was established that simultaneously estimated parameters of a one-compartment ampicillin model and a two-compartment gentamicin model. A common clearance for both drugs was used (6.89 L/h/70 kg) relating to glomerular filtration (CLGFR), with an additional clearance term added for ampicillin (5.3 L/h/70 kg). Covariate modelling included a priori allometric weight and post-menstrual age scaling of clearance. Further covariate relationships on renal clearance were postnatal age and serum creatinine.Simulation-based PKPD assessments suggest good Gram-positive (MIC ≤ 0.25 mg/L) cover. However, less than one-quarter of neonates were predicted to receive efficacious coverage against Enterobacterales (MIC ≤ 2 mg/L). The benefit of the ampicillin/gentamicin combination was limited, with only 2/23 E. coli clinical strains showing FIC index < 0.5 (synergy) and most in the range 0.5-1 (suggesting additivity). Simulations showed that feasible dosing strategies would be insufficient to cover resistant strains.

conclusionsPKPD simulations showed ampicillin and gentamicin combination therapy was insufficient to cover Enterobacterales, suggesting the need for alternative empirical treatment options for neonatal sepsis.

Indexed as

Neonatal SepsisSepsisAmpicillinAnti-Bacterial AgentsEscherichia coliGentamicinsHumansInfant, NewbornAmpicillinAnti-Bacterial AgentsGentamicins

Identifiers

PMID35107141
PMCPMC8809196
OpenAlexW4213189595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.